Revision as of 11:22, 13 May 2024

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main HER2+ breast cancer page for current regimens.

11 regimens on this page 13 variants on this page

Neoadjuvant therapy, sequential regimens

T-FEC

T-FEC: Taxol (Paclitaxel), followed by Fluorouracil, Epirubicin, Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Buzdar et al. 2005	2001-2003	Randomized (C)	TH-FEC & H	Seems to have inferior pCR rate

Chemotherapy, T portion (cycles 1 to 4)

Paclitaxel (Taxol) 225 mg/m² IV continuous infusion over 24 hours, started on day 1

Chemotherapy, FEC portion (cycles 5 to 8)

Fluorouracil (5-FU) 500 mg/m² IV once per day on days 1 & 4
Epirubicin (Ellence) 75 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 500 mg/m² IV once on day 1

21-day cycle for 8 cycles (T x 4; FEC x 4)

Subsequent treatment

Surgery

References

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. link to original article contains dosing details in manuscript PubMed
1. Update: Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. link to original article PubMed

Adjuvant therapy, sequential regimens

AC-D

AC-D: Adriamycin (Doxorubicin) & Cyclophosphamide followed by Docetaxel

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Slamon et al. 2011 (BCIRG 006)	2001-2004	Phase 3 (C)	1. AC-TH	Inferior OS
Slamon et al. 2011 (BCIRG 006)	2001-2004	Phase 3 (C)	2. TCbH	Seems to have inferior OS

Preceding treatment

Surgery

Chemotherapy, AC portion (cycles 1 to 4)

Doxorubicin (Adriamycin) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

Chemotherapy, D portion (cycles 5 to 8)

Docetaxel (Taxotere) 100 mg/m² IV over 60 minutes once on day 1

21-day cycle for 8 cycles (AC x 4; D x 4)

References

BCIRG 006: Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00021255

AC-T

AC-T: Adriamycin (Doxorubicin) & Cyclophosphamide followed by Taxol (Paclitaxel)

Regimen variant #1, weekly paclitaxel

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy	Comparative Toxicity
Romond et al. 2005 (NSABP B-31)	2000-2005	Phase 3 (C)	AC-TH	Inferior OS	Might have inferior DASI score
Romond et al. 2005 (NCCTG N9831)	2000-2005	Phase 3 (C)	1. AC-TH	Inferior OS
Romond et al. 2005 (NCCTG N9831)	2000-2005	Phase 3 (C)	2. AC-T-H	Not reported

Preceding treatment

Surgery

Chemotherapy, AC portion (cycles 1 to 4)

Doxorubicin (Adriamycin) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

Chemotherapy, T portion (cycles 5 to 16)

Paclitaxel (Taxol) 80 mg/m² IV over 60 minutes once on day 1

21-day cycle for 4 cycles, then 7-day cycle for 12 cycles (AC x 4; wP x 12)

Regimen variant #2, q3wk paclitaxel

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Romond et al. 2005 (NSABP B-31)	2000-2005	Phase 3 (C)	AC-TH	Inferior OS

Preceding treatment

Surgery

Chemotherapy, AC portion (cycles 1 to 4)

Doxorubicin (Adriamycin) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

Chemotherapy, T portion (cycles 5 to 8)

Paclitaxel (Taxol) 175 mg/m² IV over 3 hours once on day 1

21-day cycle for 8 cycles (AC x 4; T x 4)

References

NSABP B-31: Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. link to original article PubMed NCT00004067
1. Pooled update: Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. link to original article link to PMC article PubMed
2. Pooled update: Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20. link to original article link to PMC article PubMed
3. HRQoL analysis: Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. link to original article link to PMC article PubMed
NCCTG N9831: Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. link to original article PubMed NCT00005970
1. Pooled update: Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. link to original article link to PMC article PubMed
2. Update: Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. link to original article link to PMC article PubMed
3. Pooled update: Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20. link to original article link to PMC article PubMed

D-FEC

D-FEC: Docetaxel followed by Fluorouracil, Epirubicin, Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Joensuu et al. 2006 (FinHer)	2000-2003	Phase 3 (E-switch-ic)	1. TH-FEC 2. VH-FEC	Inferior RFS
Joensuu et al. 2006 (FinHer)	2000-2003	Phase 3 (E-switch-ic)	3. V-FEC	Superior DDFS

Preceding treatment

Surgery with axillary lymph node dissection or sentinel lymph node biopsy, within 12 weeks

Chemotherapy, D portion (cycles 1 to 3)

Docetaxel (Taxotere) 100 mg/m² IV over 60 minutes once on day 1

Chemotherapy, FEC portion (cycles 4 to 6)

Fluorouracil (5-FU) 600 mg/m² IV once on day 1
Epirubicin (Ellence) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

21-day cycle for 6 cycles (D x 3; FEC x 3)

References

FinHer: Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. link to original article contains dosing details in manuscript PubMed ISRCTN76560285
1. Update: Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. Epub 2009 Nov 2. link to original article PubMed

V-FEC

V-FEC: Vinorelbine followed by Fluorouracil, Epirubicin, Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Joensuu et al. 2006 (FinHer)	2000-2003	Phase 3 (C)	1. D-FEC	Inferior DDFS
Joensuu et al. 2006 (FinHer)	2000-2003	Phase 3 (C)	2. TH-FEC 3. VH-FEC	Inferior RFS

Preceding treatment

Surgery

Chemotherapy, V portion (cycles 1 to 3)

Vinorelbine (Navelbine) as follows:
- Cycles 1 & 2: 25 mg/m² IV over 5 to 10 minutes once per day on days 1, 8, 15
- Cycle 3: 25 mg/m² IV over 5 to 10 minutes once per day on days 1 & 8

Chemotherapy, FEC portion (cycles 4 to 6)

Fluorouracil (5-FU) 600 mg/m² IV once on day 1
Epirubicin (Ellence) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

21-day cycle for 6 cycles (V x 3; FEC x 3)

References

FinHer: Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. link to original article contains dosing details in manuscript PubMed ISRCTN76560285
1. Update: Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. Epub 2009 Nov 2. link to original article PubMed

Metastatic disease, first-line chemotherapy

Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.

Cyclophosphamide & Doxorubicin (AC)

AC: Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Slamon et al. 2001	1995-1997	Phase 3 (C)	1a. ACH 1b. ECH	Seems to have inferior OS

Prior treatment criteria

Slamon et al. 2001: No previous anthracycline exposure

Chemotherapy

Doxorubicin (Adriamycin) 60 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

21-day cycles

References

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article contains dosing details in manuscript PubMed

Capecitabine monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
von Minckwitz et al. 2009 (GBG 26/BIG 3-05)	2003-NR	Phase 3 (C)	Capecitabine & Trastuzumab	Seems to have inferior TTP
Geyer et al. 2006 (EGF100151)	2004-03-29 to 2005-11-15	Phase 3 (C)	Capecitabine & Lapatinib	Inferior TTP

Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm in this context.

Chemotherapy

Capecitabine (Xeloda) 1250 mg/m² PO twice per day on days 1 to 14

21-day cycles

References

EGF100151: Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. link to original article contains dosing details in manuscript PubMed NCT00078572
1. Update: Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. Epub 2008 Jan 11. link to original article PubMed
2. Update: Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. Epub 2010 Aug 24. link to original article link to PMC article PubMed
GBG 26/BIG 03-05: von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. Epub 2009 Mar 16. link to original article contains dosing details in manuscript PubMed NCT00148876
1. Update: von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 Jul 7. link to original article contains dosing details in manuscript PubMed

Docetaxel monotherapy

D: Docetaxel
T: Taxotere (Docetaxel)

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Marty et al. 2005 (M77001)	2000-2002	Randomized Phase 2 (C)	Docetaxel & Trastuzumab	Seems to have inferior OS

Chemotherapy

Docetaxel (Taxotere) 100 mg/m² IV over 60 minutes once on day 1

21-day cycles

References

M77001: Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. link to original article contains dosing details in manuscript PubMed

Cyclophosphamide & Epirubicin (EC)

EC: Epirubicin & Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Slamon et al. 2001	1995-1997	Phase 3 (C)	1a. ACH 1b. ECH	Seems to have inferior OS

Prior treatment criteria

Slamon et al. 2001: No previous anthracycline exposure

Chemotherapy

Epirubicin (Ellence) 75 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 600 mg/m² IV once on day 1

21-day cycles

References

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article contains dosing details in manuscript PubMed

Paclitaxel monotherapy, weekly

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Guan et al. 2013 (EGF104535)	2006-2009	Phase 3 (C)	TL (Taxol)	Seems to have inferior OS

Chemotherapy

Paclitaxel (Taxol) 80 mg/m² IV once per day on days 1, 8, 15

28-day cycles

References

EGF104535: Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. Epub 2013 Mar 18. link to original article contains dosing details in manuscript PubMed NCT00281658

Paclitaxel monotherapy, q3wk

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Slamon et al. 2001	1995-1997	Phase 3 (C)	TH	Seems to have inferior OS

Prior treatment criteria

Slamon et al. 2001: Previous anthracycline exposure

Chemotherapy

Paclitaxel (Taxol) 175 mg/m² IV over 3 hours once on day 1

21-day cycles

References

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article contains dosing details in manuscript PubMed

Metastatic or unresectable disease, subsequent lines

Lapatinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Blackwell et al. 2010 (EGF104900)	2005-11 to 2006-11	Phase 3 (C)	Lapatinib & Trastuzumab	Inferior PFS

¹Reported efficacy is based on the 2012 update.

Targeted therapy

Lapatinib (Tykerb) 1500 mg PO once per day on days 1 to 28

28-day cycles

References

EGF104900: Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30. Epub 2010 Feb 1. link to original article contains dosing details in manuscript PubMed NCT00320385
1. Update: Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92. Epub 2012 Jun 11. link to original article PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Breast_cancer,_HER2-positive|main HER2+ breast cancer page]] for current regimens.
+The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Breast_cancer,_HER2-positive|main HER2+ breast cancer page]] for current regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
-|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
-<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
 {{TOC limit|limit=3}}
+=Neoadjuvant therapy, sequential regimens=
-=Neoadjuvant therapy, sequential protocols=
 ==T-FEC {{#subobject:ec48df|Regimen=1}}==
 T-FEC: '''<u>T</u>'''axol (Paclitaxel), followed by '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:1350d9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 33: / Line 29: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
-====Chemotherapy, T portion====
+====Chemotherapy, T portion (cycles 1 to 4)====
-*[[Paclitaxel (Taxol)]] as follows:
+*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
-**Cycles 1 to 4: 225 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
+====Chemotherapy, FEC portion (cycles 5 to 8)====
+*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
-====Chemotherapy, FEC portion====
+*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
-*[[Fluorouracil (5-FU)]] as follows:
+*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
-**Cycles 5 to 8: 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
+'''21-day cycle for 8 cycles (T x 4; FEC x 4)'''
-*[[Epirubicin (Ellence)]] as follows:
+</div>
-**Cycles 5 to 8: 75 mg/m<sup>2</sup> IV once on day 1
+<div class="toccolours" style="background-color:#cbd5e7">
-*[[Cyclophosphamide (Cytoxan)]] as follows:
-**Cycles 5 to 8: 500 mg/m<sup>2</sup> IV once on day 1
-'''21-day cycle for 8 cycles'''
 ====Subsequent treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]]
+</div></div>
 ===References===
-# Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. [https://doi.org/10.1200/jco.2005.07.032 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15738535 PubMed]
+# Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. [https://doi.org/10.1200/jco.2005.07.032 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15738535/ PubMed]
-## '''Update:''' Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. [http://clincancerres.aacrjournals.org/content/13/1/228.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/17200359 PubMed]
+## '''Update:''' Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. [https://doi.org/10.1158/1078-0432.CCR-06-1345 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17200359/ PubMed]
+=Adjuvant therapy, sequential regimens=
-=Adjuvant therapy, sequential protocols=
 ==AC-D {{#subobject:633n67|Regimen=1}}==
 AC-D: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide followed by '''<u>D</u>'''ocetaxel
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:80c6e6|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 72: / Line 63: @@
 | style="background-color:#d73027" |Inferior OS
 |-
-|2. [[Breast_cancer,_HER2-positive#TCH_.28Docetaxel.2C_Carboplatin.29|TCH]]
+|2. [[Breast_cancer,_HER2-positive#TCbH_.28Docetaxel.29|TCbH]]
 | style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]]
-====Chemotherapy, AC portion====
+</div>
-*[[Doxorubicin (Adriamycin)]] as follows:
+<div class="toccolours" style="background-color:#b3e2cd">
-**Cycles 1 to 4: 60 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, AC portion (cycles 1 to 4)====
-*[[Cyclophosphamide (Cytoxan)]] as follows:
+*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
-**Cycles 1 to 4: 600 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, D portion (cycles 5 to 8)====
-====Chemotherapy, D portion====
+*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
-*[[Docetaxel (Taxotere)]] as follows:
+'''21-day cycle for 8 cycles (AC x 4; D x 4)'''
-**Cycles 5 to 8: 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+</div></div>
-'''21-day cycle for 8 cycles'''
 ===References===
 <!-- no pre-pub disclosed -->
-# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://doi.org/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21991949 PubMed] NCT00021255
+# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://doi.org/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21991949/ PubMed] [https://clinicaltrials.gov/study/NCT00021255 NCT00021255]
 ==AC-T {{#subobject:6ttn67|Regimen=1}}==
 AC-T: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide followed by '''<u>T</u>'''axol (Paclitaxel)
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen variant #1, weekly paclitaxel {{#subobject:80c8yg|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 17%"|Study
-!style="width: 15%"|Years of enrollment
+!style="width: 15%"|Dates of enrollment
 !style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 17%"|Comparator
@@ Line 120: / Line 109: @@
 |
 |-
-|2. [[#AC-T-H_99|AC-T-H]]
+|2. [[#AC-T-H_999|AC-T-H]]
 | style="background-color:#d3d3d3" |Not reported
 |
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]]
-====Chemotherapy, AC portion====
+</div>
-*[[Doxorubicin (Adriamycin)]] as follows:
+<div class="toccolours" style="background-color:#b3e2cd">
-**Cycles 1 to 4: 60 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, AC portion (cycles 1 to 4)====
-*[[Cyclophosphamide (Cytoxan)]] as follows:
+*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
-**Cycles 1 to 4: 600 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, T portion (cycles 5 to 16)====
-====Chemotherapy, T portion====
+*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once on day 1
-*[[Paclitaxel (Taxol)]] as follows:
+'''21-day cycle for 4 cycles, then 7-day cycle for 12 cycles (AC x 4; wP x 12)'''
-**Cycles 5 to 8: 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
+</div></div><br>
+<div class="toccolours" style="background-color:#ee6b6e">
-'''21-day cycle for 8 cycles'''
 ===Regimen variant #2, q3wk paclitaxel {{#subobject:c084f5|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 154: / Line 142: @@
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]]
-====Chemotherapy, AC portion====
+</div>
-*[[Doxorubicin (Adriamycin)]] as follows:
+<div class="toccolours" style="background-color:#b3e2cd">
-**Cycles 1 to 4: 60 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, AC portion (cycles 1 to 4)====
-*[[Cyclophosphamide (Cytoxan)]] as follows:
+*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
-**Cycles 1 to 4: 600 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+====Chemotherapy, T portion (cycles 5 to 8)====
-====Chemotherapy, T portion====
+*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
-*[[Paclitaxel (Taxol)]] as follows:
+'''21-day cycle for 8 cycles (AC x 4; T x 4)'''
-**Cycles 5 to 8: 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
+</div></div>
-'''21-day cycle for 8 cycles'''
 ===References===
 <!-- no pre-pub disclosed -->
-# '''NSABP B-31:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://doi.org/10.1056/NEJMoa052122 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16236738 PubMed] NCT00004067
+# '''NSABP B-31:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://doi.org/10.1056/NEJMoa052122 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16236738/ PubMed] [https://clinicaltrials.gov/study/NCT00004067 NCT00004067]
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [https://doi.org/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21768458 PubMed]
+## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [https://doi.org/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21768458/ PubMed]
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [https://doi.org/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25332249 PubMed]
+## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20. [https://doi.org/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25332249/ PubMed]
-## '''HRQoL analysis:''' Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. [https://doi.org/10.1200/JCO.2017.74.1165 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29072977 PubMed]
+## '''HRQoL analysis:''' Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. [https://doi.org/10.1200/JCO.2017.74.1165 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29072977/ PubMed]
 <!-- no pre-pub disclosed -->
-# '''NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://doi.org/10.1056/NEJMoa052122 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16236738 PubMed] NCT00005970
+# '''NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://doi.org/10.1056/NEJMoa052122 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16236738/ PubMed] [https://clinicaltrials.gov/study/NCT00005970 NCT00005970]
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [https://doi.org/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21768458 PubMed]
+## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [https://doi.org/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21768458/ PubMed]
-## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [https://doi.org/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22042958 PubMed]
+## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [https://doi.org/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22042958/ PubMed]
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [https://doi.org/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25332249 PubMed]
+## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20. [https://doi.org/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25332249/ PubMed]
 ==D-FEC {{#subobject:45c144|Regimen=1}}==
 D-FEC: '''<u>D</u>'''ocetaxel followed by '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
-===Protocol {{#subobject:bfeef2|Variant=1}}===
+<div class="toccolours" style="background-color:#ee6b6e">
+===Regimen {{#subobject:bfeef2|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 192: / Line 178: @@
 | rowspan="2" |[https://doi.org/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
 | rowspan="2" |2000-2003
-| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
+| rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic)
-|1. [[Breast_cancer,_HER2-positive#TH-FEC_.28Docetaxel.29|TH-FEC]]<br> 2. [[Breast_cancer,_HER2-positive#VH-FEC|VH-FEC]]
+|1. [[Breast_cancer,_HER2-positive#TH-FEC_.28Docetaxel.29|TH-FEC]]<br>2. [[Breast_cancer,_HER2-positive#VH-FEC|VH-FEC]]
 | style="background-color:#d73027" |Inferior RFS
 |-
@@ Line 200: / Line 186: @@
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]] with [[Surgery#Axillary_lymph_node_dissection|axillary lymph node dissection]] or [[Surgery#Sentinel_lymph_node_biopsy|sentinel lymph node biopsy]], within 12 weeks
+</div>
-====Chemotherapy, D portion====
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy, D portion (cycles 1 to 3)====
 *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+====Chemotherapy, FEC portion (cycles 4 to 6)====
-'''21-day cycle for 3 cycles'''
-====Chemotherapy, FEC portion====
 *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
 *[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
 *[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycle for 6 cycles (D x 3; FEC x 3)'''
-'''21-day cycle for 3 cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
-# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://doi.org/10.1056/NEJMoa053028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16495393 PubMed] ISRCTN76560285
+# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://doi.org/10.1056/NEJMoa053028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16495393/ PubMed] ISRCTN76560285
-## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [https://doi.org/10.1200/JCO.2008.21.4577 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19884557 PubMed]
+## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. Epub 2009 Nov 2. [https://doi.org/10.1200/JCO.2008.21.4577 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19884557/ PubMed]
 ==V-FEC {{#subobject:84c1e0|Regimen=1}}==
 V-FEC: '''<u>V</u>'''inorelbine followed by '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
-===Protocol {{#subobject:712969|Variant=1}}===
+<div class="toccolours" style="background-color:#ee6b6e">
+===Regimen {{#subobject:712969|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 240: / Line 225: @@
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Surgery]]
-====Chemotherapy, V portion====
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy, V portion (cycles 1 to 3)====
 *[[Vinorelbine (Navelbine)]] as follows:
 **Cycles 1 & 2: 25 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1, 8, 15
 **Cycle 3: 25 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1 & 8
+====Chemotherapy, FEC portion (cycles 4 to 6)====
-'''21-day cycle for 3 cycles'''
-====Chemotherapy, FEC portion====
 *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
 *[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
 *[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycle for 6 cycles (V x 3; FEC x 3)'''
-'''21-day cycle for 3 cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
-# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://doi.org/10.1056/NEJMoa053028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16495393 PubMed] ISRCTN76560285
+# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://doi.org/10.1056/NEJMoa053028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16495393/ PubMed] ISRCTN76560285
-## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [https://doi.org/10.1200/JCO.2008.21.4577 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19884557 PubMed]
+## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. Epub 2009 Nov 2. [https://doi.org/10.1200/JCO.2008.21.4577 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19884557/ PubMed]
-=Adjuvant chemotherapy=
-==Paclitaxel monotherapy, weekly {{#subobject:5218a|Regimen=1}}==
-T: '''<u>T</u>'''axol (Paclitaxel)
-<br>P: '''<u>P</u>'''aclitaxel
-<br>pT: '''<u>p</u>'''acli'''<u>T</u>'''axel
-<br>wP: '''<u>w</u>'''eekly '''<u>P</u>'''aclitaxel
-<br>wT: '''<u>w</u>'''eekly '''<u>T</u>'''axol (Paclitaxel)
-===Regimen {{#subobject:6b14dd|Variant=1}}===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 17%"|Study
-!style="width: 15%"|Years of enrollment
-!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 17%"|Comparator
-!style="width: 17%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-!style="width: 17%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]]
-|-
-|[https://doi.org/10.1056/NEJMoa052122 Romond et al. 2005 (NCCTG N9831)]
-|2000-2005
-| style="background-color:#1a9851" |Phase 3 (C)
-|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
-|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
-| style="background-color:#d3d3d3" |
-|-
-|}
-''Note: This paclitaxel dosing schedule was used for all patients in NCCTG N9831. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
-====Preceding treatment====
-*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Cyclophosphamide_.26_Doxorubicin_.28AC.29_2|AC]] x 4
-====Chemotherapy====
-*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
-'''21-day cycle for 4 cycles'''
-====Subsequent treatment====
-*NCCTG N9831: [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy_2|H]] x 52 versus no further treatment
-===References===
-<!-- no pre-pub disclosed -->
-# '''NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://doi.org/10.1056/NEJMoa052122 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16236738 PubMed] NCT00005970
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [https://doi.org/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21768458 PubMed]
-## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [https://doi.org/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22042958 PubMed]
-## '''Pooled update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [https://doi.org/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25332249 PubMed]
 =Metastatic disease, first-line chemotherapy=
-'''''Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.''
+''Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.''
 ==Cyclophosphamide & Doxorubicin (AC) {{#subobject:843320|Regimen=1}}==
 AC: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:2e4988|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 320: / Line 261: @@
 |1995-1997
 | style="background-color:#1a9851" |Phase 3 (C)
-|[[Breast_cancer,_HER2-positive#ACH|ACH]]
+|1a. [[Breast_cancer,_HER2-positive#ACH|ACH]]<br>1b. [[Breast_cancer,_HER2-positive#ECH_2|ECH]]
 | style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |}
-''Note: patients in Slamon et al. 2001 had not previously received adjuvant (postoperative) therapy with an anthracycline.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Slamon et al. 2001: No previous anthracycline exposure
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
 *[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
-# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11248153 PubMed]
+# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11248153/ PubMed]
 ==Capecitabine monotherapy {{#subobject:bd9beb|Regimen=1}}==
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:f3e92c|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 351: / Line 295: @@
 |-
 |[https://doi.org/10.1056/NEJMoa064320 Geyer et al. 2006 (EGF100151)]
-|2004-2005
+|2004-03-29 to 2005-11-15
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[Breast_cancer,_HER2-positive#Capecitabine_.26_Lapatinib|Capecitabine & Lapatinib]]
@@ Line 357: / Line 301: @@
 |-
 |}
-''To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm in this context.''
+''Note: To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm in this context.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''EGF100151:''' Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [https://doi.org/10.1056/NEJMoa064320 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17192538 PubMed] NCT00078572
+# '''EGF100151:''' Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [https://doi.org/10.1056/NEJMoa064320 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17192538/ PubMed] [https://clinicaltrials.gov/study/NCT00078572 NCT00078572]
-## '''Update:''' Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. [http://link.springer.com/article/10.1007/s10549-007-9885-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18188694 PubMed]
+## '''Update:''' Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. Epub 2008 Jan 11. [http://link.springer.com/article/10.1007/s10549-007-9885-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18188694/ PubMed]
-## '''Update:''' Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. [http://theoncologist.alphamedpress.org/content/15/9/924.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20736298 PubMed]
+## '''Update:''' Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. Epub 2010 Aug 24. [https://doi.org/10.1634/theoncologist.2009-0181 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20736298/ PubMed]
-# '''GBG 26/BIG 03-05:''' von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. Epub 2009 Mar 16. [https://doi.org/10.1200/jco.2008.19.6618 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19289619 PubMed] NCT00148876
+# '''GBG 26/BIG 03-05:''' von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. Epub 2009 Mar 16. [https://doi.org/10.1200/jco.2008.19.6618 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19289619/ PubMed] [https://clinicaltrials.gov/study/NCT00148876 NCT00148876]
-## '''Update:''' von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 Jul 7. [https://www.ejcancer.com/article/S0959-8049(11)00425-4 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21741829 PubMed]
+## '''Update:''' von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 Jul 7. [https://doi.org/10.1016/j.ejca.2011.06.021 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21741829/ PubMed]
 ==Docetaxel monotherapy {{#subobject:47db8e|Regimen=1}}==
 D: '''<u>D</u>'''ocetaxel
 <br>T: '''<u>T</u>'''axotere (Docetaxel)
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:bf6578|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 383: / Line 328: @@
 |[https://doi.org/10.1200/jco.2005.04.173 Marty et al. 2005 (M77001)]
 |2000-2002
-| style="background-color:#1a9851" |Phase 3 (C)
+| style="background-color:#1a9851" |Randomized Phase 2 (C)
 |[[Breast_cancer,_HER2-positive#Docetaxel_.26_Trastuzumab_.28TH.29_3|Docetaxel & Trastuzumab]]
 | style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''M77001:''' Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. [https://doi.org/10.1200/jco.2005.04.173 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15911866 PubMed]
+# '''M77001:''' Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. [https://doi.org/10.1200/jco.2005.04.173 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15911866/ PubMed]
 ==Cyclophosphamide & Epirubicin (EC) {{#subobject:b81844|Regimen=1}}==
 EC: '''<u>E</u>'''pirubicin & '''<u>C</u>'''yclophosphamide
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:8466d6|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 409: / Line 355: @@
 |1995-1997
 | style="background-color:#1a9851" |Phase 3 (C)
-|[[Breast_cancer,_HER2-positive#ECH_2|ECH]]
+|1a. [[Breast_cancer,_HER2-positive#ACH|ACH]]<br>1b. [[Breast_cancer,_HER2-positive#ECH_2|ECH]]
 | style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Slamon et al. 2001: No previous anthracycline exposure
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
 *[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+'''21-day cycles'''
-'''21-day cycle for up to 6 to 8 cycles'''
+</div></div>
 ===References===
-# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11248153 PubMed]
+# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11248153/ PubMed]
 ==Paclitaxel monotherapy, weekly {{#subobject:3e5448|Regimen=1}}==
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:b70577|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 438: / Line 389: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
 '''28-day cycles'''
+</div></div>
 ===References===
 <!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and at the 36th Annual European Society of Medical Oncology Congress, Stockholm, Sweden, September 23-27, 2011. -->
-# '''EGF104535:''' Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. Epub 2013 Mar 18. [https://doi.org/10.1200/JCO.2011.40.5241 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23509322 PubMed] NCT00281658
+# '''EGF104535:''' Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. Epub 2013 Mar 18. [https://doi.org/10.1200/JCO.2011.40.5241 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23509322/ PubMed] [https://clinicaltrials.gov/study/NCT00281658 NCT00281658]
 ==Paclitaxel monotherapy, q3wk {{#subobject:3e5448|Regimen=1}}==
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:72389a|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 463: / Line 414: @@
 |-
 |}
-''Note: patients in EGF30001 were NOT required to be HER2-positive.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Prior treatment criteria====
+*Slamon et al. 2001: Previous anthracycline exposure
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
-# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11248153 PubMed]
+# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://doi.org/10.1056/NEJM200103153441101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11248153/ PubMed]
+=Metastatic or unresectable disease, subsequent lines=
+==Lapatinib monotherapy {{#subobject:9beyv2|Regimen=1}}==
+<div class="toccolours" style="background-color:#ee6b6e">
+===Regimen {{#subobject:agc2bb|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1200/jco.2008.21.4437 Blackwell et al. 2010 (EGF104900)]
+|2005-11 to 2006-11
+|style="background-color:#1a9851"|Phase 3 (C)
+|[[Breast_cancer,_HER2-positive#Lapatinib_.26_Trastuzumab_3|Lapatinib & Trastuzumab]]
+| style="background-color:#d73027" |Inferior PFS
+|-
+|}
+''<sup>1</sup>Reported efficacy is based on the 2012 update.''
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Lapatinib (Tykerb)]] 1500 mg PO once per day on days 1 to 28
+'''28-day cycles'''
+</div></div>
+===References===
+<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL, and the 33rd Annual Meeting of the European Society for Medical Oncology, September 12-16, 2008, Stockholm, Sweden. -->
+# '''EGF104900:''' Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30. Epub 2010 Feb 1. [https://doi.org/10.1200/jco.2008.21.4437 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20124187/ PubMed] [https://clinicaltrials.gov/study/NCT00320385 NCT00320385]
+## '''Update:''' Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92. Epub 2012 Jun 11. [https://doi.org/10.1200/jco.2011.35.6725 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22689807/ PubMed]
 [[Category:Breast cancer regimens]]
 [[Category:Historical regimens]]

Difference between revisions of "Breast cancer, HER2-positive - historical"

Revision as of 11:22, 13 May 2024

Neoadjuvant therapy, sequential regimens

T-FEC

Regimen

Chemotherapy, T portion (cycles 1 to 4)

Chemotherapy, FEC portion (cycles 5 to 8)

Subsequent treatment

References

Adjuvant therapy, sequential regimens

AC-D

Regimen

Preceding treatment

Chemotherapy, AC portion (cycles 1 to 4)

Chemotherapy, D portion (cycles 5 to 8)

References

AC-T

Regimen variant #1, weekly paclitaxel

Preceding treatment

Chemotherapy, AC portion (cycles 1 to 4)

Chemotherapy, T portion (cycles 5 to 16)

Regimen variant #2, q3wk paclitaxel

Preceding treatment

Chemotherapy, AC portion (cycles 1 to 4)

Chemotherapy, T portion (cycles 5 to 8)

References

D-FEC

Regimen

Preceding treatment

Chemotherapy, D portion (cycles 1 to 3)

Chemotherapy, FEC portion (cycles 4 to 6)

References

V-FEC

Regimen

Preceding treatment

Chemotherapy, V portion (cycles 1 to 3)

Chemotherapy, FEC portion (cycles 4 to 6)

References

Metastatic disease, first-line chemotherapy

Cyclophosphamide & Doxorubicin (AC)

Regimen

Prior treatment criteria

Chemotherapy

References

Capecitabine monotherapy

Regimen

Chemotherapy

References

Docetaxel monotherapy

Regimen

Chemotherapy

References

Cyclophosphamide & Epirubicin (EC)

Regimen

Prior treatment criteria

Chemotherapy

References

Paclitaxel monotherapy, weekly

Regimen

Chemotherapy

References

Paclitaxel monotherapy, q3wk

Regimen

Prior treatment criteria

Chemotherapy

References

Metastatic or unresectable disease, subsequent lines

Lapatinib monotherapy

Regimen

Targeted therapy

References

Navigation menu

Search